These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30460997)

  • 1. Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice.
    Vermeer NS; Giezen TJ; Zastavnik S; Wolff-Holz E; Hidalgo-Simon A
    Clin Pharmacol Ther; 2019 Apr; 105(4):962-969. PubMed ID: 30460997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions.
    Correia Pinheiro L; Giezen TJ; Wolff-Holz E; Weise M; Laslop A; Hidalgo-Simon A
    Clin Pharmacol Ther; 2021 Nov; 110(5):1311-1317. PubMed ID: 34472087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of biological medicines as compared with non-biologicals: an analysis of the italian spontaneous reporting system database.
    Cutroneo PM; Isgrò V; Russo A; Ientile V; Sottosanti L; Pimpinella G; Conforti A; Moretti U; Caputi AP; Trifirò G
    Drug Saf; 2014 Nov; 37(11):961-70. PubMed ID: 25255847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
    Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
    Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is pharmacovigilance of biologicals cost-effective?
    Claus B
    Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current state of biologic pharmacovigilance in the European Union: improvements are needed.
    Felix T; Jordan JB; Akers C; Patel B; Drago D
    Expert Opin Drug Saf; 2019 Mar; 18(3):231-240. PubMed ID: 30714424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Traceability of biologicals: present challenges in pharmacovigilance.
    Vermeer NS; Spierings I; Mantel-Teeuwisse AK; Straus SM; Giezen TJ; Leufkens HG; Egberts TC; De Bruin ML
    Expert Opin Drug Saf; 2015 Jan; 14(1):63-72. PubMed ID: 25369769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
    Francescon S; Fornasier G; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologicals and biosimilars: safety issues in Europe.
    Portela MDCC; Sinogas C; Albuquerque de Almeida F; Baptista-Leite R; Castro-Caldas A
    Expert Opin Biol Ther; 2017 Jul; 17(7):871-877. PubMed ID: 28540760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UK.
    Klein K; Hazell L; Stolk P; Shakir S
    Drug Saf; 2020 Mar; 43(3):255-263. PubMed ID: 31872358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study.
    Vermeer NS; Ebbers HC; Straus SM; Leufkens HG; Egberts TC; De Bruin ML
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):297-306. PubMed ID: 26676881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopharmaceuticals safety perception in Slovakia: considerations and real-life pharmacovigilance data.
    Lassanova M; Liskova S; Tisonova J; Fundarkova S; Lassan S
    Bratisl Lek Listy; 2021; 122(7):443-448. PubMed ID: 34161110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacovigilance of Biologics in a Multisource Environment.
    Sagi S; Cohen HP; Woollett GR
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1249-1254. PubMed ID: 29172979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biologicals and Biosimilars: Gaps in the Pharmacovigilance System in Portugal].
    Portela MC; Sinogas C; Almeida FA; Baptista-Leite R; Castro-Caldas A
    Acta Med Port; 2017 Mar; 30(3):205-212. PubMed ID: 28550830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases.
    Vermeer NS; Straus SM; Mantel-Teeuwisse AK; Domergue F; Egberts TC; Leufkens HG; De Bruin ML
    Drug Saf; 2013 Aug; 36(8):617-25. PubMed ID: 23771794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
    Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
    BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland.
    O'Callaghan J; Griffin BT; Morris JM; Bermingham M
    BioDrugs; 2018 Jun; 32(3):267-280. PubMed ID: 29721705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EU's new pharmacovigilance legislation: considerations for biosimilars.
    Calvo B; Zuñiga L
    Drug Saf; 2014 Jan; 37(1):9-18. PubMed ID: 24190573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.